Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 17-Nov-22 9:02 PM View:  | Gruskin Daniel Chief Medical Officer | Logicbio Therapeutics, Inc. (LOGC) | 16-Nov-22 | Disposition | 3,331 | -- | -- | (100%) 3.33K to 0 | |
| 17-Nov-22 9:10 PM View: | Chereau Frederic President, CEO Director | Logicbio Therapeutics, Inc. (LOGC) | 16-Nov-22 | Disposition | 253,811 | -- | -- | (100%) 253.81K to 0 | |
| 17-Nov-22 9:14 PM View: | Kay Mark A Director | Logicbio Therapeutics, Inc. (LOGC) | 16-Nov-22 | Disposition | 784,557 | -- | -- | (100%) 784.56K to 0 | |
| 17-Nov-22 9:04 PM View: | Chen Leon Director | Logicbio Therapeutics, Inc. (LOGC) | 16-Nov-22 | Disposition | 22,333 | -- | -- | (100%) 22.33K to 0 | |
| 17-Nov-22 9:11 PM View: | Wyzga Michael S Director | Logicbio Therapeutics, Inc. (LOGC) | 16-Nov-22 | Disposition | 3,141 | -- | -- | (100%) 3.14K to 0 | |
| 17-Nov-22 9:09 PM View: | Moscicki Richard A Director | Logicbio Therapeutics, Inc. (LOGC) | 16-Nov-22 | Disposition | 3,916 | -- | -- | (100%) 3.92K to 0 | |
| 17-Nov-22 9:13 PM View: | Enyedy Mark J Director | Logicbio Therapeutics, Inc. (LOGC) | 16-Nov-22 | Disposition | 2,921 | -- | -- | (100%) 2.92K to 0 | |
| 13-Jan-22 6:36 PM View: | Jones Cecilia Chief Financial Officer | Logicbio Therapeutics, Inc. (LOGC) | 12-Jan-22 | Payment of Exercise | 2,175 | $2.01 | $4,371.75 | (37%) 5.94K to 3.76K | |
| 13-Jan-22 6:36 PM View: | Jones Cecilia Chief Financial Officer | Logicbio Therapeutics, Inc. (LOGC) | 11-Jan-22 | Option Exercise | 5,939 | -- | -- | 100% 0 to 5.94K | |
| 10-Aug-21 6:31 PM View: | Gruskin Daniel Chief Medical Officer | Logicbio Therapeutics, Inc. (LOGC) | 09-Aug-21 | Market Option Sale | 1,467 | $4.35 | $6,381.45 | (31%) 4.8K to 3.33K | |
| 10-Aug-21 6:31 PM View: | Gruskin Daniel Chief Medical Officer | Logicbio Therapeutics, Inc. (LOGC) | 06-Aug-21 | Option Exercise | 4,798 | -- | -- | 100% 0 to 4.8K | |
| 19-Apr-21 9:00 PM View: | Chereau Frederic President and Chief Executive Director | Logicbio Therapeutics, Inc. (LOGC) | 16-Apr-21 | Market Option Sale | 7,542 | $5.73 | $43,215.70 | (3%) 261.35K to 253.81K | |
| 19-Apr-21 9:00 PM View: | Chiang Kyle Chief Operating Officer | Logicbio Therapeutics, Inc. (LOGC) | 16-Apr-21 | Market Option Sale | 2,977 | $5.73 | $17,058.20 | (11%) 26.36K to 23.39K | |
| 19-Apr-21 9:00 PM View: | Chereau Frederic President and Chief Executive Director | Logicbio Therapeutics, Inc. (LOGC) | 15-Apr-21 | Option Exercise | 23,414 | -- | -- | 10% 237.94K to 261.35K | |
| 19-Apr-21 9:00 PM View: | Chiang Kyle Chief Operating Officer | Logicbio Therapeutics, Inc. (LOGC) | 15-Apr-21 | Option Exercise | 9,360 | -- | -- | 55% 17.0K to 26.36K | |
| 04-Jan-21 7:00 PM View: | Wyzga Michael S Director | Logicbio Therapeutics, Inc. (LOGC) | 01-Jan-21 | Option Exercise | 3,141 | -- | -- | 100% 0 to 3.14K | |
| 04-Jan-21 7:00 PM View: | Kay Mark A Director | Logicbio Therapeutics, Inc. (LOGC) | 01-Jan-21 | Option Exercise | 2,199 | -- | -- | 100% 0 to 2.2K | |
| 04-Jan-21 7:00 PM View: | Enyedy Mark J Director | Logicbio Therapeutics, Inc. (LOGC) | 01-Jan-21 | Option Exercise | 2,921 | -- | -- | 100% 0 to 2.92K | |
| 04-Jan-21 7:00 PM View: | Moscicki Richard A Director | Logicbio Therapeutics, Inc. (LOGC) | 01-Jan-21 | Option Exercise | 3,916 | -- | -- | 100% 0 to 3.92K | |
| 04-Jan-21 7:00 PM View: | Chen Leon Director | Logicbio Therapeutics, Inc. (LOGC) | 01-Jan-21 | Option Exercise | 3,298 | -- | -- | 100% 0 to 3.3K | |
| 14-Dec-20 8:35 PM View: | O'Connell Daniel P Director | Logicbio Therapeutics, Inc. (LOGC) | 10-Dec-20 | Option Exercise | 2,513 | -- | -- | 100% 0 to 2.51K | |
| 05-Oct-20 5:36 PM View: | Orbimed Advisors LLC Director 10% Owner | Logicbio Therapeutics, Inc. (LOGC) | 01-Oct-20 | Market Purchase Duplicate | 1,481,480 | $6.00 | $8,888,890.00 | 23% 6.47M to 7.95M | 31% |
| 05-Oct-20 5:32 PM View: | Chimovits Erez Director 10% Owner | Logicbio Therapeutics, Inc. (LOGC) | 01-Oct-20 | Market Purchase | 1,481,480 | $6.00 | $8,888,890.00 | 23% 6.47M to 7.95M | 31% |
| 05-Oct-20 5:00 PM View: | Arix Bioscience Plc 10% Owner | Logicbio Therapeutics, Inc. (LOGC) | 28-Sep-20 | Market Sale | 273,584 | $7.54 | $2,061,870.00 | (10%) 2.66M to 2.38M | (4%) |
| 05-Oct-20 5:00 PM View: | Arix Bioscience Plc 10% Owner | Logicbio Therapeutics, Inc. (LOGC) | 25-Sep-20 | Market Sale | 174,219 | $7.08 | $1,232,950.00 | (6%) 2.83M to 2.66M | (11%) |
| 05-Oct-20 5:00 PM View: | Arix Bioscience Plc 10% Owner | Logicbio Therapeutics, Inc. (LOGC) | 24-Sep-20 | Market Sale | 38,514 | $7.63 | $293,823.00 | (1%) 2.87M to 2.83M | (3%) |
| 05-Oct-20 5:00 PM View: | Arix Bioscience Plc 10% Owner | Logicbio Therapeutics, Inc. (LOGC) | 13-Aug-20 | Market Sale | 159 | $8.75 | $1,391.25 | (< 1%) 2.87M to 2.87M | 10% |
| 05-Oct-20 5:00 PM View: | Arix Bioscience Plc 10% Owner | Logicbio Therapeutics, Inc. (LOGC) | 12-Aug-20 | Market Sale | 1,335 | $8.79 | $11,734.70 | (< 1%) 2.87M to 2.87M | 11% |
| 05-Oct-20 5:00 PM View: | Arix Bioscience Plc 10% Owner | Logicbio Therapeutics, Inc. (LOGC) | 29-Jul-20 | Market Sale | 2,709 | $8.78 | $23,787.70 | (< 1%) 2.87M to 2.87M | 11% |
| 05-Oct-20 5:00 PM View: | Arix Bioscience Plc 10% Owner | Logicbio Therapeutics, Inc. (LOGC) | 22-Jul-20 | Market Sale | 22,651 | $9.00 | $203,950.00 | (< 1%) 2.89M to 2.87M | 13% |
| 05-Oct-20 5:00 PM View: | Arix Bioscience Plc 10% Owner | Logicbio Therapeutics, Inc. (LOGC) | 20-Jul-20 | Market Sale | 36,983 | $9.25 | $342,056.00 | (1%) 2.93M to 2.89M | 15% |
| 05-Oct-20 5:00 PM View: | Arix Bioscience Plc 10% Owner | Logicbio Therapeutics, Inc. (LOGC) | 17-Jul-20 | Market Sale | 31,101 | $9.24 | $287,373.00 | (1%) 2.96M to 2.93M | 15% |
| 05-Oct-20 5:00 PM View: | Arix Bioscience Plc 10% Owner | Logicbio Therapeutics, Inc. (LOGC) | 16-Jul-20 | Market Sale | 16,332 | $8.56 | $139,786.00 | (< 1%) 2.98M to 2.96M | 8% |
| 29-Aug-19 4:15 PM View: | Wilton Thomas Chief Business Officer | Logicbio Therapeutics, Inc. (LOGC) | 27-Aug-19 | Option Exercise | 75,000 | $0.73 | $54,750.00 | 100% 0 to 75.0K | |
| 25-Oct-18 6:25 PM View: | Ioannidou Sofia Director | Logicbio Therapeutics, Inc. (LOGC) | 23-Oct-18 | Conversion | 1,367,410 | -- | -- | 100% 0 to 1.37M | |
| 25-Oct-18 6:28 PM View: | Orbimed Advisors LLC Director 10% Owner | Logicbio Therapeutics, Inc. (LOGC) | 23-Oct-18 | Conversion | 5,276,780 | -- | -- | 92% 5.77M to 11.04M | |
| 25-Oct-18 6:25 PM View: | Ioannidou Sofia Director | Logicbio Therapeutics, Inc. (LOGC) | 23-Oct-18 | Purchase | 420,000 | $10.00 | $4,200,000.00 | 31% 1.37M to 1.79M | |
| 25-Oct-18 6:28 PM View: | Orbimed Advisors LLC Director 10% Owner | Logicbio Therapeutics, Inc. (LOGC) | 23-Oct-18 | Purchase | 1,190,000 | $10.00 | $11,900,000.00 | 11% 11.04M to 12.23M | |
| 25-Oct-18 6:25 PM View: | O'Connell Daniel P Director | Logicbio Therapeutics, Inc. (LOGC) | 23-Oct-18 | Conversion | 2,279,020 | -- | -- | 100% 0 to 2.28M | |
| 26-Oct-18 9:29 AM View: | Arix Bioscience Plc 10% Owner | Logicbio Therapeutics, Inc. (LOGC) | 23-Oct-18 | Conversion Duplicate | 2,279,020 | -- | -- | 100% 0 to 2.28M | |
| 25-Oct-18 6:25 PM View: | O'Connell Daniel P Director | Logicbio Therapeutics, Inc. (LOGC) | 23-Oct-18 | Purchase | 700,000 | $10.00 | $7,000,000.00 | 31% 2.28M to 2.98M | |
| 26-Oct-18 9:29 AM View: | Arix Bioscience Plc 10% Owner | Logicbio Therapeutics, Inc. (LOGC) | 23-Oct-18 | Purchase Duplicate | 700,000 | $10.00 | $7,000,000.00 | 31% 2.28M to 2.98M | |
| 25-Oct-18 6:24 PM View: | Chimovits Erez Director | Logicbio Therapeutics, Inc. (LOGC) | 23-Oct-18 | Conversion | 2,997,760 | -- | -- | 100% 0 to 3.0M | |
| 25-Oct-18 6:27 PM View: | Kariv Tomer Director | Logicbio Therapeutics, Inc. (LOGC) | 23-Oct-18 | Conversion Duplicate | 1,367,410 | -- | -- | 42% 3.26M to 4.63M | |
| 25-Oct-18 6:24 PM View: | Chimovits Erez Director | Logicbio Therapeutics, Inc. (LOGC) | 23-Oct-18 | Purchase | 490,000 | $10.00 | $4,900,000.00 | 16% 3.0M to 3.49M | |
| 25-Oct-18 6:27 PM View: | Kariv Tomer Director | Logicbio Therapeutics, Inc. (LOGC) | 23-Oct-18 | Purchase Duplicate | 420,000 | $10.00 | $4,200,000.00 | 9% 4.63M to 5.05M |
